Outlook Therapeutics Inc.’s filing revealed that its Director HILZINGER KURT J acquired Company’s shares for reported $46827.0 on Mar 01. In the deal valued at $1.69 per share,27,708 shares were bought. As a result of this transaction, HILZINGER KURT J now holds 273,117 shares worth roughly $ 0.29 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, HILZINGER KURT J bought 6,000 shares, generating $9,600 in total proceeds. Upon buying the shares at $1.60, the Director now owns 245,409 shares.
Before that, HILZINGER KURT J bought 41,160 shares. Outlook Therapeutics Inc. shares valued at $60,094 were divested by the Director at a price of $1.46 per share. As a result of the transaction, HILZINGER KURT J now holds 239,409 shares, worth roughly $0.25 million.
Meanwhile, Ladenburg Thalmann initiated its Outlook Therapeutics Inc. [OTLK] rating to a Buy in a research note published on Tuesday, September 11, 2019; the price target was $9. PT values the company’s stock at a premium of 88.33 to its Tuesday closing price. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in mid May with a ‘”an Outperform”‘ rating. Ascendiant Capital Markets began covering OTLK with a “Buy” recommendation on April 22, 2019.
Price Performance Review of OTLK
On Tuesday, Outlook Therapeutics Inc. [NASDAQ:OTLK] saw its stock jump 5.16% to $1.05. On the same session, the stock had its day’s lowest price of $0.9555, but rose to a high of $1.09. Over the last five days, the stock has gained 14.85%. Outlook Therapeutics Inc. shares have fallen nearly -22.79% since the year began. Nevertheless, the stocks have fallen -57.14% over the past one year. While a 52-week high of $3.27 was reached on 03/18/22, a 52-week low of $0.68 was recorded on 05/31/22. SMA at 50 days reached $1.4449, while 200 days put it at $1.6897. A total of 0.53 million shares were traded, compared to the trading of 0.65 million shares in the previous session.
Levels Of Support And Resistance For OTLK Stock
The 24-hour chart illustrates a support level at 0.9737, which if violated will result in even more drops to 0.8973. On the upside, there is a resistance level at 1.1082. A further resistance level may holdings at 1.1663. The Relative Strength Index (RSI) on the 14-day chart is 41.82, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0088, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 18.53%. Stochastics %K at 62.34% indicates the stock is a holding.
How much short interest is there in Outlook Therapeutics Inc.?
A steep rise in short interest was recorded in Outlook Therapeutics Inc. stocks on Apr 28, 2022, growing by 1.0 million shares to a total of 10.68 million shares. Yahoo Finance data shows the prior-month short interest on Mar 30, 2022 was 9.68 million shares. There was a rise of 9.36%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 7.54% of the overall stock float, the days-to-cover ratio (short ratio) rose to 10.28.
Outlook Therapeutics Inc. [OTLK] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 6,227,218 shares, or roughly 2.76% of the outstanding OTLK shares. In other words, the investor’s shares have risen by 757,349 from its previous 13-F filing of 5469869.0. Additionally, The Vanguard Group, Inc. decreased -6.20% of its stake after which the total value it holdings stand at $6,238,676, while Geode Capital Management LLC added 21.57% of its stake to hold $2.14 million in the firm. Over the last quarter, LVW Advisors LLC sold 0 shares of Outlook Therapeutics Inc., while SSgA Funds Management, Inc. sold 99,312 shares. At present, Vista Finance LLC is holding 983,645 shares valued at $1.13 million. Northern Trust Investments, Inc. owned 981,485 shares of the company at the time of its most recent 13F filing, worth $1.13 million.
According to FactSet, Outlook Therapeutics Inc.’s share price will average $6.58 in the next year, based on opinions of analysts polled by the firm. This is up nearly 500.0 percent from its previous closing price of $1.00. Analysts expect Outlook Therapeutics Inc. stock to reach the higher price of $7.75, while the lowest price estimate is $6.00. However, 3 analysts have rated OTLK stock as a Buy in their predictions for 2022.